Tricarboxylic acids and derivatives
Search Within Results
1
–
2
of
2
results
1
Medchemexpress LLC Pacritinib (citrate) | 1228923-42-9 | 99.7% | 664.70 | 1 ML
Pacritinib (SB1518) citrate is a potent inhibitor of both wild-type JAK2 (IC50=23 nM) and JAK2V617F mutant (IC50=19 nM). It also inhibits FLT3 (IC50=22 nM) and its mutant FLT3D835Y (IC50=6 nM). This compound can be used for the research of acute myeloid leukemia (AML) and myelofibrosis (MF).
- Potent inhibitor of wild-type JAK2 (IC50=23 nM)
- Potent inhibitor of JAK2V617F mutant (IC50=19 nM)
- Inhibits FLT3 (IC50=22 nM)
- Inhibits FLT3D835Y mutant (IC50=6 nM)
- Used for research in acute myeloid leukemia (AML) and myelofibrosis (MF)
2
Medchemexpress LLC Pacritinib citrate | 1228923-42-9 | 99.7% | 664.70 | 5 MG
Pacritinib citrate is a potent inhibitor of both wild-type JAK2 (IC50=23 nM) and JAK2V617F mutant (IC50=19 nM). It also inhibits FLT3 (IC50=22 nM) and its mutant FLT3D835Y (IC50=6 nM). Pacritinib citrate can be used for the research of acute myeloid leukemia (AML) and myelofibrosis (MF).
- Potent inhibitor of wild-type JAK2 (IC50=23 nM)
- Potent inhibitor of JAK2V617F mutant (IC50=19 nM)
- Inhibits FLT3 (IC50=22 nM)
- Inhibits FLT3D835Y mutant (IC50=6 nM)
- Can be used for the research of acute myeloid leukemia (AML)
- Can be used for the research of myelofibrosis (MF)